Human Biological Samples Sourcing: An Overview


By: Mathini Ilancheran. -- Senior Research Analyst,

30 June, 2015

Human Biological Samples Sourcing: An Overview

later by the researchers to study the disease progression to bring about potential benefits to the patient community. Despite the varying regulations, HBS collection and biobanking has evolved throughout the years. The Biospecimen collected encompasses important information such as phenotypic, genomic, proteomic related to a specific population or a specific disease. Utilization of this information in research has led to innovative drugs, creating personalized medicine according to the patient?s genetic profile. Animal models have been used in discovery and pre-clinical research stages to obtain data which can be extrapolated to apply in human conditions. The animal model does not reiterate the effects precisely in humans as they differ in the metabolism and are exposed to environmental factors.1 Alternatives like the human tissue can reduce the overall early development research costs. Instead of using animal models for toxicity testing, use of donated human tissues had a precision rate of 85%, hence enabling accurate information when compared to the experiments in animal models.2 Big pharmaceutical companies are seen to partner with both commercial and public biobanks for sample procurement and genotyping. The recent deal between AstraZeneca and Montreal Institute to genotype up to 80,000 patients for genes associated with cardiovascular diseases and diabetes is one good example of collaborative effort within the HBS market.3


COVID-19: Assess impact on your suppliers and ensure business continuity with Beroe’s WIRE
(World Instant Risk Exposure)